DelistingOct 21, 2026, 04:38 PM
Alaunos Therapeutics Regains Nasdaq Compliance After $350M Financing and Merger
AI Summary
Alaunos Therapeutics, Inc. announced it has regained compliance with the Nasdaq Stockholders' Equity Requirement following a significant $350 million financing. The company had been at risk of delisting due to insufficient equity. The financing, which closed on October 14, 2026, included the completion of its merger with Velaris Therapeutics, Inc. A key aspect of the financing involved a waiver from an investor regarding cash settlement rights for preferred stock, which helped bolster the company's equity position.
Key Highlights
- Alaunos Therapeutics regained compliance with Nasdaq's Stockholders' Equity Requirement following a $350 million financing.
- The company had previously received a delisting notice due to insufficient stockholders' equity.
- A hearing before the Nasdaq Hearings Panel was scheduled for November 10, 2026.
- The company completed a merger with Velaris Therapeutics, Inc. on October 13, 2026.
- A private placement of common and convertible preferred stock raised approximately $350 million.
- A waiver was obtained from Fairmount Fund II regarding cash settlement rights for Series C Preferred Stock.
Price Impact
More from TCRT